BREAKING NEWS

Intec Pharma Announces Development Collaboration With Global Pharmaceutical Company

Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has entered into a Feasibility and Option agreement with Novartis
Pharmaceuticals to explore using the Accordion Pill platform for a proprietary Novartis compound. The details of the therapeutic area or specific compound were not released. Following potentially successful feasibility studies including a Phase 1 PK study, Novartis has the option to enter into negotiations with respect to a potential licensing agreement for employing Intec Pharma Accordion Pill™ technology.

"We are delighted to work with Novartis in potentially utilizing our Accordion Pill platform technology," said Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma. "Over the past few years, the Accordion Pill has demonstrated impressive clinical results in applications for drugs with both a narrow absorption window and poor solubility. As the company grows, we hope to increase the number of partners who ask us to formulate Accordion Pills for their proprietary compounds."

About Intec Pharma Ltd.  
Intec Pharma is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company's Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company's product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is being developed for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients, and AP-CBD/THC, an Accordion Pill with the two primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC), which is being developed for various indications including low back neuropathic pain and fibromyalgia.

Read Similar Articles

0 Comments Write your comment

    1. Loading...